The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Characterization of the novel SARS‐CoV‐2 Omicron (B.1.1.529) variant of concern and its global perspective
Abstract
As the latest identified novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variant of concern (VOC), the influence of Omicron on our globe grows promptly. Compared with the last VOC (Delta variant), more mutations were identified, which may address the characteristics of Omicron. Considering these crucial mutations and their implications including an increase in transmissibility, COVID‐19 severity, and reduction of efficacy of currently available diagnostics, vaccines, and therapeutics, Omicron has been classified as one of the VOC. Notably, 15 of these mutations reside in the receptor‐binding domain of spike glycoprotein, which may alter transmissibility, infectivity, neutralizing antibody escape, and vaccine breakthrough cases of COVID‐19. Therefore, our present study characterizes the mutational hotspots of the Omicron variant in comparison with the Delta variant of SARS‐CoV‐2. Furthermore, detailed information was analyzed to characterize the global perspective of Omicron, including transmission dynamic, effect on testing, and immunity, which shall promote the progress of the clinical application and basic research. Collectively, our data suggest that due to continuous variation in the spike glycoprotein sequences, the use of coronavirus‐specific attachment inhibitors may not be the current choice of therapy for emerging SARS‐CoV‐2 VOCs. Hence, we need to proceed with a sense of urgency in this matter.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009 · cited 1×
“Asn679Lys is close to the furin cleavage site and contributes to its polybasic character, which may enhance spike cleavage and help transmission.(8,19) It is still unsure how well the Omicron variant can be transmitted from one person to another person.”
BackgroundChen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies
Wilhelm, A., Widera, M., Grikscheit, K., Toptan, T., Schenk, B., Pallas, C., Metzler, M., Kohmer, N., Hoehl, S., Helfritz, F. A., et al. (2021) · doi:10.1101/2021.12.07.21267432 · Cited by 440
NATIONAL INSTITUTE OF COMMUNICABLE DISEASES
Smith, C. E. G., & Fairweather, D. V. I. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92052-1 · Cited by 384
Kumar, S., Maurya, V. K., Prasad, A. K., Bhatt, M. L. B., & Saxena, S. K. (2020) · VirusDisease · doi:10.1007/s13337-020-00571-5 · Cited by 227
Self-citationHigh genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
Schmidt, F., Weisblum, Y., Rutkowska, M., Poston, D., DaSilva, J., Zhang, F., Bednarski, E., Cho, A., Schaefer-Babajew, D. J., Gaebler, C., et al. (2021) · Nature · doi:10.1038/s41586-021-04005-0 · Cited by 215
Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2
O'Toole, Á., Hill, V., Pybus, O. G., Watts, A., Bogoch, I. I., Khan, K., Messina, J. P., The COVID-19 Genomics UK (COG-UK) consortium, Network for Genomic Surveillance in South Africa (NGS-SA), Brazil-UK CADDE Genomic Network, et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16661.1 · Cited by 192
Petersen, E., Ntoumi, F., Hui, D. S., Abubakar, A., Kramer, L. D., Obiero, C., Tambyah, P. A., Blumberg, L., Yapi, R., Al-Abri, S., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.11.040 · Cited by 187
The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant
Ali, F., Kasry, A., & Amin, M. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2021.100086 · Cited by 163
Where did ‘weird’ Omicron come from?
Kupferschmidt, K. (2021) · Science · doi:10.1126/science.acx9738 · Cited by 154
Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review
Somerville, M., Curran, J., Dol, J., Boulos, L., Saxinger, L. M., Doroshenko, A., Hastings, S. E., Reynolds, B., Gallant, A. J., Shin, H. D., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-055781 · Cited by 37
Chasing COVID-19 through SARS-CoV-2 spike glycoprotein
Saxena, S. K., Kumar, S., Baxi, P., Srivastava, N., Puri, B., & Ratho, R. K. (2020) · VirusDisease · doi:10.1007/s13337-020-00642-7 · Cited by 25
Self-citationStructural and molecular perspectives of SARS-CoV-2
Kumar, S., & Saxena, S. K. (2021) · Methods · doi:10.1016/j.ymeth.2021.03.007 · Cited by 25
Self-citationTherapeutic approaches for SARS-CoV-2 infection
Gupta, A., Pradhan, A., Maurya, V. K., Kumar, S., Theengh, A., Puri, B., & Saxena, S. K. (2021) · Methods · doi:10.1016/j.ymeth.2021.04.026 · Cited by 24
Self-citation
Cited by
Araf, Y., Akter, F., Tang, Y., Fatemi, R., Parvez, M. S. A., Zheng, C., & Hossain, M. G. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27588 · Cited by 862
Khandia, R., Singhal, S., Alqahtani, T., Kamal, M. A., El-Shall, N. A., Nainu, F., Desingu, P. A., & Dhama, K. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112816 · Cited by 300
Structural biology of SARS-CoV-2: open the door for novel therapies
Yan, W., Zheng, Y., Zeng, X., He, B., & Cheng, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00884-5 · Cited by 291
Bignon, E., Marazzi, M., Grandemange, S., & Monari, A. (2022) · Chemical Science · doi:10.1039/d2sc00108j · Cited by 13
Chaudhuri, A., Das, S., & Chakrabarti, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.137154
Metadata
- Authors
- Saxena, S. K., Kumar, S., Ansari, S., Paweska, J. T., Maurya, V. K., Tripathi, A. K., & Abdel‐Moneim, A. S.
- Venue
- Journal of Medical Virology
- Publisher
- Wiley
- Published
- 2022-01-11
- Volume
- 94
- Issue
- 4
- Pages
- 1738-1744
- ISSN
- 0146-6615 (ISSN-L)
- 1096-9071
- OpenAlex
- W4200112411
- Cited by
- 294
- References
- 16
- FWCI
- 20.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.